Clinical trial Recruiting at 5 sites Observational Ages 18 and up

Investigating infections in critically ill patients on continuous renal replacement therapy

Official title: The Effect of Filter Lifespan in Continuous Renal Replacement Therapy on the Rate of New Infections in Critically Ill Patients: a Prospective, Multicenter, Observational Trial

Run by University Hospital Muenster · NCT05450185 · Data updated 2026-11-12

This study looks at critically ill patients on a special kidney treatment to see how often they get new infections and what might cause them.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment600 (estimated)
SponsorUniversity Hospital Muenster
Academic / other
Locations5 sites (Innsbruck and 4 other locations)
StatusRecruiting
StartedMarch 2, 2023
Main results expectedMay 2025
Study endsAugust 2025
Registry record updatedDecember 12, 2024
Trial IDNCT05450185 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adult patients aged 18 and older who are critically ill with dialysis-dependent AKI and receiving CRRT.

Probably not a fit

Patients with chronic kidney disease, chronic dialysis dependency, or those with certain immunosuppressive conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on critically ill patients undergoing continuous renal replacement therapy (CRRT) for acute kidney injury (AKI). It aims to analyze the incidence and characteristics of new infections associated with CRRT, as well as the factors influencing these infections. The study is based on findings from a post-hoc analysis of the RICH trial, which suggested a link between filter lifespan and infection rates. By understanding these dynamics, the research seeks to improve patient outcomes in the ICU setting.

Why it matters

Potential benefit: If successful, this study could lead to improved management strategies for infections in critically ill patients receiving CRRT.

How similar studies have gone: While there have been studies on CRRT, this specific investigation into the relationship between filter lifespan and infection rates is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adult patients (age ≥18 years)
* Critically ill patients with dialysis-dependent AKI
* Continuous renal replacement therapy (CRRT)
* Written informed consent

Exclusion Criteria:

* Chronic kidney disease with estimated glomerular filtration rate (eGFR)\<30ml/min/1.73m2
* Chronic dialysis dependency
* Kidney transplant
* (Glomerulo-)nephritis, interstitial nephritis, vasculitis
* Patients on immunosuppression
* Patients with chronic inflammatory diseases (e.g. arthritis, HIV, chronic hepatitis)
* Persons with any kind of dependency on the investigator or employed by the sponsor or investigator

Where it's running

  • Univ.-Klinik Innsbruck
    Innsbruck, Austria
    Recruiting
  • Universidade de São Paulo
    São Paulo, Brazil
    Recruiting
  • Universitätsklinikum Erlangen-Nürnberg, Abteilung für Nephrologie und Hypertensiologie
    Erlangen, Germany
    Recruiting
  • Kliniken Maria Hilf, Klinik für Anästhesiologie und Operative Intensivmedizin
    Mönchengladbach, Germany
    Recruiting
  • University Hospital Muenster
    Münster, Germany
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.